Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...

As Lindsey Vonn’s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the ...

Researchers found an antibody that seems to play a role in people with better lung cancer prognoses, but turning it into a ...

NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the plan to initiate a Phase 2 clinical trial evaluating monoclonal antibody ...

Considering a switch from IVIg to SCIg for primary immunodeficiency? Explore differences in responsibility, side effects, ...

Cone Health rethinking infusion aligns services, standardizes workflows and boosts capacity across oncology and non-oncology sites.

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

One patient still in remission 3 years after single infusion of base-edited CAR7 T cells ...

Five-year results suggest Hemgenix may help reduce bleeding in hemophilia B. Many patients needed far fewer factor IX infusions after treatment. Most maintained stable factor IX levels, with generally ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press ...

The approval of subcutaneous amivantamab can offer a more accessible means of treatment for patients with non–small cell lung cancer (NSCLC). The subcutaneous approval for amivantamab is a significant ...